pyrazines has been researched along with Kidney Diseases in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (17.02) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (17.02) | 29.6817 |
| 2010's | 29 (61.70) | 24.3611 |
| 2020's | 2 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, T; Anzai, N; Mishima, E; Miyazaki, M | 1 |
| Fenioux, C; Funck-Brentano, C; Gligorov, J; Gougis, P; Solas, C; Spano, JP; Veyri, M | 1 |
| Kuang, W; Lan, Z; Zhang, X; Zhu, W | 1 |
| Chan, NG; Hsia, CC | 1 |
| Chen, W; Chen, Z; Gong, D; Huang, X; Liu, Z; Wang, Q; Zeng, C; Zhang, H | 1 |
| Alloway, RR; Cardi, MA; Krisl, JC; Shields, AR; Woodle, ES | 1 |
| Abar, F; Dibb, J; Dibb, W; Frires, R; Heitner, SB; Kovacsovics, T; Maziarz, RT; Meyers, G; Perez-Avraham, G; Scott, EC; Smith, SD; Stentz, A | 1 |
| Davidson, MM; Gong, X; Hei, TK; Ivanov, VN | 1 |
| Shibayama, H | 1 |
| Basnayake, K; Talbot, B; Wright, D | 1 |
| Abu Jawdeh, BG; Alloway, RR; Brailey, P; Cardi, MA; Ejaz, NS; Girnita, A; Govil, A; Mogilishetty, G; Roy-Chaudhury, P; Sadaka, B; Shields, AR; Walsh, RC; Woodle, ES | 1 |
| Budde, K; Lehner, LJ | 1 |
| Takahashi, N | 1 |
| Basset, M; Foli, A; Gillmore, J; Hawkins, P; Lachmann, H; Merlini, G; Milani, P; Palladini, G; Sachchithanantham, S; Wechalekar, AD | 1 |
| Bender, S; Bonaud, A; Bridoux, F; Cogné, M; Delpy, L; Druilhe, A; Javaugue, V; Lacombe, C; Oblet, C; Quellard, N; Sirac, C; Srour, N; Touchard, G | 1 |
| Cruz, HG; Dingemanse, J; Halabi, A; Kaufmann, P; Krause, A; Ulč, I | 1 |
| Bladé, J; Cibeira, MT; Fernández de Larrea, C; Lloreta, J; Mascaró, JM; Rovira, M; Serra, N; Solé, M; Torras, A | 1 |
| Eller, K; Heininger, D; Huber, JM; Mayer, G; Rosenkranz, AR; Tagwerker, A | 1 |
| Cheng, F; Feng, L; Guo, Y; Ke, N; Li, Q; Li, S; Li, Y | 1 |
| Decaux, O; Karras, A | 1 |
| Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P | 1 |
| Chaudhary, R; Ghose, A; Taj, A; Tariq, Z | 1 |
| Aull, MJ; Dadhania, D; Hartono, C; Kapur, S; Saal, S | 1 |
| Bhalodia, Y; Manek, R; Sheth, N; Vaghasiya, J | 1 |
| Haga, M; Miwa, A; Nagata, A; Noto, S; Sekiguchi, N; Takezako, N | 1 |
| Alvarez Fernández, GM; de Alarcón Jiménez, RM; García Hernández, MA; Jimeno Griñó, C; Molina Núñez, M; Navarro Parreño, MJ; Roca Meroño, S; Zarco Pedrinaci, E | 1 |
| Davies, A; Egorin, MJ; Hamilton, A; Ivy, SP; Leal, TB; Lenz, HJ; LoRusso, PA; Mani, S; Mier, J; Mulkerin, D; Neuwirth, R; Ramanathan, RK; Remick, SC; Sarantopoulos, J; Shibata, S; Takimoto, CH; Venkatakrishnan, K; von Moltke, L; Wright, JJ | 1 |
| Bladé, J; Cakana, A; Comenzo, RL; Dubrey, SW; Elsayed, Y; Enny, C; Fermand, JP; Hassoun, H; Heffner, LT; Hegenbart, U; Liu, X; Merlini, G; Mortimer, S; Palladini, G; Ramaswami, P; Reece, DE; Sanchorawala, V; Van De Velde, H; Vescio, RA | 1 |
| Bellovich, K; El-Ghoroury, M; Goel, SK; Granger, D; Marin, M; Qu, H | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I | 1 |
| Benjamin, M; Gibbs, S | 1 |
| Bridoux, F; Delbes, S; Desport, E; Fermand, JP; Jaccard, A; Pourreau, F; Puyade, M; Sirac, C; Touchard, G | 1 |
| Eiam-Ong, S; Susantitaphong, P; Tiranathanagul, K | 1 |
| Juul, JS; Larsen, T; Marcussen, N; Pedersen, EB | 1 |
| Hildebrandt, GC; Panu, LD; Shahan, JL | 1 |
| Li, Y; Shi, J; Sun, L; Wang, X | 1 |
| Dang, SC; Qu, JG; Wang, XQ; Zhang, JX | 1 |
| Arizio, A | 1 |
| Beyer, KH; Vesell, ES | 1 |
| Weinman, EJ | 1 |
| Bennett, WM; Houghton, DC; Porter, GA; Purnell, J | 1 |
| Ford, EJ | 1 |
| Haddow, A; Ross, WC; Timmis, GM | 1 |
| Balant, L; Fabre, J; Gorgia, A; Schwarz, R; Zahnd, G | 1 |
| Kaiser, I | 1 |
| Sanjo, T | 1 |
5 review(s) available for pyrazines and Kidney Diseases
| Article | Year |
|---|---|
Uric Acid Elevation by Favipiravir, an Antiviral Drug.
Topics: Aldehyde Oxidase; Amides; Antiviral Agents; Biotransformation; Coronavirus Infections; COVID-19; Drug Interactions; Humans; Hyperuricemia; Kidney; Kidney Diseases; Molecular Structure; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Pandemics; Pneumonia, Viral; Pyrazines; Uric Acid; Xanthine Oxidase | 2020 |
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Humans; Hypercalcemia; Kidney Diseases; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2014 |
[Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chronic Disease; Combined Modality Therapy; Dexamethasone; Down-Regulation; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin lambda-Chains; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Remission Induction; Renal Dialysis; Transplantation, Autologous | 2011 |
[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Topics: Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Heart Transplantation; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Kidney; Kidney Diseases; Kidney Transplantation; Melphalan; Paraproteinemias; Plasma Exchange; Pyrazines | 2012 |
Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus.
Topics: Animals; Antihypertensive Agents; Biological Transport, Active; Diabetes Mellitus, Type 2; Guanidines; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Kidney Diseases; Pyrazines; Rats | 2000 |
5 trial(s) available for pyrazines and Kidney Diseases
| Article | Year |
|---|---|
Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Rate; Transplantation, Autologous | 2014 |
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Topics: Acetamides; Acetates; Adult; Aged; Antihypertensive Agents; Area Under Curve; Case-Control Studies; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Prospective Studies; Pyrazines; Receptors, Epoprostenol; Severity of Illness Index | 2016 |
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Treatment Outcome | 2009 |
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Diseases; Humans; Kidney Diseases; Liver Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Treatment Outcome | 2011 |
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
37 other study(ies) available for pyrazines and Kidney Diseases
| Article | Year |
|---|---|
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxychloroquine; Immunosuppression Therapy; Kidney Diseases; Long QT Syndrome; Lopinavir; Neoplasms; Pandemics; Pneumonia, Viral; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Ligustrazine modulates renal cysteine biosynthesis in rats exposed to cadmium.
Topics: Aldehydes; Animals; Cadmium; Cystathionine beta-Synthase; Cysteine; Environmental Pollutants; Glutathione; Glutathione Disulfide; Kidney; Kidney Diseases; Male; Malondialdehyde; Methionine Adenosyltransferase; Protective Agents; Pyrazines; Rats, Sprague-Dawley | 2017 |
Light chain deposition.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light Chains; Kidney Diseases; Kidney Tubules; Male; Multiple Myeloma; Prognosis; Pyrazines | 2013 |
Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept.
Topics: Abatacept; Adult; Azathioprine; Biopsy; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Cyclosporine; Glomerulonephritis, IGA; Graft Rejection; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Male; Prednisone; Pyrazines; Treatment Outcome | 2014 |
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Topics: Adult; Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Diseases; Lenalidomide; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proteasome Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Tetramethylpyrazine (TMP) protects against sodium arsenite-induced nephrotoxicity by suppressing ROS production, mitochondrial dysfunction, pro-inflammatory signaling pathways and programed cell death.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Arsenites; Autophagy; Biomarkers; Cell Line; Cytoprotection; Dose-Response Relationship, Drug; Glutathione; Humans; Inflammation Mediators; Kidney Diseases; Kidney Tubules, Proximal; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Pyrazines; Reactive Oxygen Species; Signal Transduction; Sodium Compounds; Time Factors | 2015 |
The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Electrophoresis; Humans; Immunoglobulin Light Chains; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Pyrazines; Thalidomide | 2014 |
Prospective iterative trial of proteasome inhibitor-based desensitization.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Desensitization, Immunologic; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Histocompatibility Testing; HLA Antigens; Humans; Immunoglobulins, Intravenous; Kidney Diseases; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Prognosis; Prospective Studies; Proteasome Inhibitors; Pyrazines; Risk Factors; Rituximab; Young Adult | 2015 |
Bortezomib-based antibody reduction therapy: the first step to “true” desensitization?
Topics: Boronic Acids; Desensitization, Immunologic; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Kidney Diseases; Male; Proteasome Inhibitors; Pyrazines | 2015 |
[Multiple myeloma and renal impairment].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Kidney Diseases; Multiple Myeloma; Paraproteinemias; Prognosis; Pyrazines | 2015 |
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.
Topics: Amyloid; Amyloidosis; Boronic Acids; Bortezomib; Cooperative Behavior; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Europe; Heart Diseases; Humans; Kidney Diseases; Pyrazines; Treatment Outcome | 2015 |
A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression; Genetic Loci; Heavy Chain Disease; Humans; Immunoglobulin Heavy Chains; Kidney Diseases; Kidney Glomerulus; Mice; Mice, Transgenic; Molecular Sequence Data; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Aggregation, Pathological; Protein Structure, Tertiary; Pyrazines; Sequence Deletion; Unfolded Protein Response | 2015 |
Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda Monoclonal Gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Immunoglobulin G; Kidney Diseases; Kidney Glomerulus; Lung; Male; Middle Aged; Paraproteinemias; Pyrazines | 2009 |
The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Boronic Acids; Bortezomib; CD4 Lymphocyte Count; Creatinine; Cyclin-Dependent Kinase Inhibitor p21; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intravenous; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Necrosis; Nephritis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reperfusion Injury; Time Factors | 2009 |
The protective mechanism of ligustrazine against renal ischemia/reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Disease Models, Animal; Gene Expression; Intercellular Adhesion Molecule-1; Kidney; Kidney Diseases; Kidney Transplantation; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Neutrophils; Oxidative Stress; Peroxidase; Pyrazines; Reperfusion Injury; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2011 |
[Update in multiple myeloma: international criteria for treatment response and renal complications].
Topics: Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; France; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Immunologic Factors; International Cooperation; Kidney Diseases; Multiple Myeloma; Practice Guidelines as Topic; Prevalence; Pyrazines; Renal Dialysis; Renal Insufficiency; Sensitivity and Specificity; Societies, Medical | 2009 |
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide | 2010 |
Acute dyspnea from treatment of AL amyloidisis with bortezomib.
Topics: Acute Disease; Aged; Amyloidosis; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Dyspnea; Humans; Kidney Diseases; Male; Middle Aged; Protease Inhibitors; Pyrazines | 2011 |
Modulation of antibody response in a sensitized patient with ongoing antibody-mediated injury.
Topics: ABO Blood-Group System; Adult; Boronic Acids; Bortezomib; Female; Histocompatibility Testing; HLA Antigens; HLA-DQ Antigens; HLA-DR Antigens; HLA-DRB4 Chains; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Diseases; Kidney Transplantation; Lupus Erythematosus, Systemic; Male; Protease Inhibitors; Pyrazines; Reoperation; Siblings; Tissue Donors; Treatment Failure | 2009 |
Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes.
Topics: Animals; Apoptosis; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA Fragmentation; Female; Glutathione; Glutathione Peroxidase; Kidney; Kidney Diseases; Lipid Peroxidation; Male; Oxidative Stress; Peroxidase; Pyrazines; Rats; Rats, Wistar; Reperfusion Injury; Sitagliptin Phosphate; Superoxide Dismutase; Triazoles; Xanthine Oxidase | 2011 |
[Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl].
Topics: Aged; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome | 2011 |
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Female; Humans; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2011 |
Myeloma cast nephropathy: a rare cause of primary renal allograft dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Survival; Humans; Kidney Diseases; Kidney Transplantation; Multiple Myeloma; Plasmapheresis; Pyrazines; Remission Induction | 2011 |
Amyloidosis.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Delayed Diagnosis; Dexamethasone; Dyspnea; Heart Diseases; Humans; Kidney; Kidney Diseases; Male; Narration; Pyrazines; Quality of Life; Serum Amyloid A Protein; Thalidomide | 2011 |
Extended high cutoff on-line hemodiafiltration is superior to extended high cutoff hemodialysis in removal of free light chain immunoglobulin of myeloma cast nephropathy.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hemodiafiltration; Humans; Immunoglobulin Light Chains; Kidney; Kidney Diseases; Multiple Myeloma; Pyrazines | 2012 |
[Improved prognosis in light chain nephropathy due to multiple myeloma].
Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Kidney Diseases; Middle Aged; Multiple Myeloma; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation | 2012 |
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatine Kinase, MM Form; Cyclohexanecarboxylic Acids; Dexamethasone; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunologic Factors; Kidney Diseases; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Pravastatin; Pyrazines; Rhabdomyolysis; Thalidomide | 2012 |
Protective effects of ligustrazine on ischemia-reperfusion injury in rat kidneys.
Topics: Animals; Disease Models, Animal; Endothelin-1; Free Radical Scavengers; Kidney; Kidney Diseases; Malondialdehyde; Pyrazines; Random Allocation; Rats; Rats, Wistar; Renal Artery; Reperfusion Injury; Superoxide Dismutase | 2002 |
Ligustrazine alleviates acute renal injury in a rat model of acute necrotizing pancreatitis.
Topics: Acute Disease; Animals; Disease Models, Animal; Kidney Diseases; Pancreatitis, Acute Necrotizing; Pyrazines; Rats; Rats, Sprague-Dawley; Renal Circulation; Vasodilator Agents | 2006 |
[Ambulatory therapy of tuberculosis].
Topics: Adaptation, Psychological; Ambulatory Care; Drug Administration Schedule; Humans; Kidney Diseases; Pyrazines; Rifampin; Socioeconomic Factors; Tuberculosis | 1984 |
Uric acid and the kidney.
Topics: Acute Kidney Injury; Ammonia; Animals; Glomerular Filtration Rate; Glutamine; Gout; Humans; Hydrogen-Ion Concentration; Kidney; Kidney Calculi; Kidney Diseases; Kidney Failure, Chronic; Kidney Tubules; Metabolic Diseases; Pyrazines; Uric Acid | 1976 |
Effect of amiloride on experimental gentamicin nephrotoxicity.
Topics: Amiloride; Animals; Diet; Drug Interactions; Gentamicins; Inulin; Kidney; Kidney Cortex; Kidney Diseases; Kidney Tubules; Magnesium; Male; Necrosis; Potassium; Pyrazines; Rats; Rats, Inbred F344; Risk | 1985 |
Activity of gamma-glutamyl transpeptidase and other enzymes in the serum of sheep with liver or kidney damage.
Topics: Alcohol Oxidoreductases; Animals; Arginase; Aspartate Aminotransferases; Bilirubin; Brain; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Female; gamma-Glutamyltransferase; Glutamate Dehydrogenase; Indoles; Intestine, Small; Kidney; Kidney Diseases; Ligation; Liver; Liver Diseases; Male; Mercury Poisoning; Muscles; Mycotoxins; Myocardium; Pancreas; Pyrazines; Pyrroles; Sheep; Sheep Diseases; Urea | 1974 |
The chain of unexpected discovery: xanthopterin-stimulated renal mitosis.
Topics: Animals; Biochemistry; Creativity; History, 20th Century; Hyperplasia; Hypertrophy; Hypoxanthines; Kidney; Kidney Diseases; Mitosis; Pteridines; Purines; Pyrazines; Pyrimidines; Quinoxalines; Rats; Stimulation, Chemical; Structure-Activity Relationship; United Kingdom; Xanthine Oxidase; Xanthopterin | 1972 |
Pharmacokinetics of glipizide in man: influence of renal insufficiency.
Topics: Administration, Oral; Blood Glucose; Carbon Radioisotopes; Chromatography, Paper; Chromatography, Thin Layer; Cyclohexanes; Feces; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Injections, Intravenous; Insulin; Kidney Diseases; Male; Pyrazines; Sulfonylurea Compounds | 1973 |
[Treatment of chronic low serum potassium levels in potassium losing kidney by amiloride (author's transl)].
Topics: Administration, Oral; Adult; Amiloride; Chronic Disease; Diuretics; Drug Evaluation; Humans; Hypokalemia; Kidney; Kidney Diseases; Male; Potassium; Potassium Chloride; Pyrazines | 1974 |
[New diuretics--amiloride].
Topics: Animals; Chemical Phenomena; Chemistry; Diuretics; Heart Diseases; Humans; Hypertension; Kidney Diseases; Liver Cirrhosis; Pyrazines | 1970 |